Comienzos
keyboard_arrow_right
keyboard_arrow_right
The SERVE-HF trial shows.
Reports

The SERVE-HF trial shows.

Related StoriesUnderstanding the causes of sudden loss of life in epilepsy: an interview with Professor Sanjay SisodiyaLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanBrain health: how will you decrease cognitive decline? An interview with Heather Snyder, Ph.D.After a median follow-up of 31 weeks ASV efficiently treated central sleep apnoea but had no effect on the primary end point, which was a combined mix of all-cause death, life-saving cardiovascular intervention, or unplanned hospitalisation for worsening heart failure.Any modification in gene expression and behaviour of the immune cells will then be analysed to recognize biomarkers connected with TB an infection and/or TB re-activation. These details would be specifically pertinent to clinicians and experts as current testing cannot reliably detect if the individual is at risk of developing the disease. Furthermore, the identification of predictive biomarkers may also help clinicians accurately assess patients’ responses to TB treatment and deal appropriately with anyone who has developed drug resistance to Mycobacterium tuberculosis, the bacterium in charge of causing TB. This will result in early and accurate evaluation of the potency of treatment in TB individuals. One of the lead researchers involved in the collaboration is Prof Paola Castagnoli, Scientific Director of SIgN.